This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Holland Pharma, FACO merger faces in-depth probe

( July 4, 2016, 15:07 GMT | Official Statement) -- MLex Summary: The Dutch competition authority has said plans by Holland Pharma to buy FACO would require an in-depth merger probe. The authority is concerned about high market shares post-merger on the market for the wholesale of drugstore products. The probe can start when Holland Pharma applies to the regulator for an in-depth review.Nader onderzoek nodig naar overname FACO door Holland Pharma...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login